Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolism
US-2024384272-A1 · Nov 21, 2024 · US
Oral delivery of therapeutically effective LNA oligonucleotides
US9364495B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9364495-B2 |
| Application number | US-201013503189-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 20, 2010 |
| Priority date | Oct 20, 2009 |
| Publication date | Jun 14, 2016 |
| Grant date | Jun 14, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a disorder selected from the group consisting of hyperlipidemia, HDL/LDL cholesterol imbalance, dyslipidemia, coronary artery disease (CAD), coronary heart disease (CHD), and atherosclerosis, comprising orally administering a composition comprising an LNA oligomer that targets ApoB and a penetration enhancer selected from the group consisting of: a fatty acid, a bile acid, a chelating agent, an anionic cationic surfactant, and a no…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9364495B2 cover?
- The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
- Who is the assignee on this patent?
- Hardee Gregroy, Straarup Ellen Marie, Lindholm Marie Wickstrom, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/712. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).